Clinical Trial Update: Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of sacituzumab govitecan-hziy (IMMU-132) in adults with epithelial cancers; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Breast
• Cervical Cancer
• Endometrial Cancer
• Esophageal Cancer
• Gastric Adenocarcinoma
• Glioblastoma Multiforme
• Head and Neck Cancers - Squamous Cell
• Hepatocellular Carcinoma
• Hormone-refractory Prostate Cancer
• Non-small Cell Lung Cancer
• Ovarian Epithelial Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma
• Small Cell Lung Cancer
• Triple-negative Breast Cancer
• Urinary Bladder Neoplasms

Drugs mentioned

• Sacituzumab govitecan-hziy (sacituzumab govitecan-hziy)

Snippet

Sponsor: Gilead Sciences | Conditions: Gastric Adenocarcinoma, Esophageal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-04-06